[关键词]
[摘要]
目前，玻璃体腔注射抗血管内皮生长因子(VEGF)药物已成为治疗视网膜静脉阻塞和糖尿病视网膜病变等视网膜血管性疾病相关黄斑水肿的一线治疗方案，但存在治疗效果差异化、疗效持续性不足等局限性。作为应用于眼科的首个双特异性抗体药物，Faricimab通过同时靶向VEGF-A和血管生成素-2(Ang-2)双通路，展现出良好的治疗效果。文章基于近年临床试验及真实世界研究数据，系统阐述了Faricimab治疗糖尿病性黄斑水肿(DME)、视网膜静脉阻塞性黄斑水肿(RVO-ME)及难治性黄斑水肿的研究进展，并分别探讨其相较于其他抗VEGF药物的优势。同时，结合Faricimab的安全性特征及未来发展趋势，对其在视网膜血管疾病性黄斑水肿治疗领域的前景进行展望。文章旨在为临床优化治疗策略提供循证参考，助力降低黄斑水肿致盲风险。
[Key word]
[Abstract]
Intravitreal injection of anti-vascular endothelial growth factor(VEGF)agents has become the primary treatment for macular edema associated with retinal vascular disease such as diabetic retinopathy and retinal vein occlusion, but there are limitations such as variable treatment efficacy and insufficient durability of therapeutic effects. As the first bispecific antibody applied in ophthalmic treatment, Faricimab achieves favorable outcomes by simultaneously targeting both VEGF-A and angiopoietin-2(Ang-2)pathways. Based on evidence from recent clinical trials and real-world studies, this article reviews the research progress on Faricimab for the treatment of diabetic macular edema(DME), retinal vein occlusion-associated macular edema(RVO-ME)and refractory macular edema compared to the therapeutic effects of other agents. Additionally, based on Faricimab's safety characteristics and future potential, its therapeutic prospects for macular edema associated with retinal vascular diseases are discussed. This review aims to provide evidence-based references for optimizing clinical treatment strategies, thereby contributing to mitigating the risk of vision loss due to macular edema.
[中图分类号]
[基金项目]
山东省医药卫生科技发展计划项目(No.2019WS333); 滨州医学院科技计划项目(No.BY2020KJ56); 滨州医学院教学改革与研究立项项目(No.JYKTLX202284)
